“A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis” (2019) SKIN The Journal of Cutaneous Medicine, 3(2), p. 171. doi:10.25251/skin.3.2.11.